CEL-SCI Corp SEC Filings

Lincoln Alternative Strategies LLC reported beneficial ownership of 555,000 shares of CEL-SCI Corporation common stock, representing 6.94% of the outstanding class. The filing states the reporter is organized in Delaware and holds sole voting and dispositive power over these shares. The report also includes a certification that the shares were not acquired to change or influence control of the issuer and are not held in connection with such transactions. The disclosure identifies the position as passive ownership under the Schedule 13G framework and provides the reporter's signature by its managing member.

Cel-Sci (CVM) prospectus supplement excerpt reports clinical outcomes from a trial with dates noted: June 30, 2025 and August 22, 2025. The results state no lymph node involvement by PET imaging and low PD-L1 tumor expression (TPS <10) on biopsy. Treated patients showed a 0.349 hazard ratio for death versus control (95% CI [0.18, 0.66], Wald p=0.0012), representing a 28.6% absolute 5-year overall survival benefit versus control (p=0.0015) and a stated risk-of-death reduction of about one-half at five years. The data also report greater than 35% rates of pre-surgery tumor reductions and/or downstages (p<0.01). The excerpt contrasts the low PD-L1 context with settings where Keytruda and Opdivo work best (high PD-L1).

Cel-Sci Corporation (CVM) prospectus supplement excerpt highlights clinical and securities details. The text states the company’s product candidates are intended to be given immediately after diagnosis and before any other treatment, including surgery. Clinical outcomes cited include a reduction in risk of death by half at five years versus control, a 28.6% absolute 5-year overall survival benefit (p=0.0015), and a hazard ratio of 0.349 versus control with 95% CIs [0.18, 0.66] (Wald p=0.0012). The excerpt also reports a >35% rate of pre-surgery tumor reductions and/or downstages (p<0.01) and notes activity in tumors with low PD-L1 expression (TPS <10), where some checkpoint inhibitors are less effective.

The filing excerpt discloses that 546,894 shares of common stock are issuable upon exercise of outstanding stock options as of June 30, 2025, at a weighted average exercise price of $195.06 per share. The text includes dates (June 30, 2025; August 22, 2025) and a Bloomberg market reference link but does not provide offering size, proceeds, or complete prospectus financial tables in this excerpt.

Cel‑Sci Corporation (CVM) reported unaudited results for the quarterly period ended June 30, 2025. Total assets were $20.34 million versus $26.99 million a year earlier, driven by a cash decline to $1.79 million from $4.74 million. The company recorded a nine‑month net loss of $19.31 million compared to $20.81 million in the prior year; research and development expense was $12.18 million and general and administrative expense was $6.59 million. Cash used in operating activities totaled $12.45 million while proceeds from issuance of common stock and pre‑funded warrants were $12.56 million during the period. Management discloses substantial doubt about the company’s ability to continue as a going concern and estimates about $30 million will be required to finance the planned 212‑patient confirmatory Multikine study. A 30‑for‑1 reverse stock split became effective in May 2025 and shares outstanding were 5,321,341 at June 30, 2025. Subsequent to period end the company sold 1,500,000 shares for approximately $5.7 million.

CEL-SCI Corporation (NYSE American: CVM) has filed Amendment No. 1 to a Form S-3 shelf registration, enabling the company to issue up to $100 million of common stock, preferred stock (including convertibles), rights, warrants and/or units on a continuous basis. Pricing, size, and underwriter details will be set in future prospectus supplements.

The document retroactively reflects the 1-for-30 reverse stock split effected 20 May 2025, which cut outstanding shares from roughly 94 million to about 3.1 million while leaving authorised share counts unchanged. CEL-SCI lists 6,882,156 post-split shares outstanding as of 4 Aug 2025; the stock last closed at $9.25.

Net proceeds are earmarked primarily to advance lead immunotherapy Multikine®. In a Phase III trial’s target subgroup (no nodal involvement; low PD-L1) Multikine delivered 73 % 5-year survival versus 45 % for standard of care (hazard ratio 0.35). The FDA has cleared a 212-patient confirmatory registration study, potentially allowing an accelerated approval filing once fully enrolled.

CEL-SCI is a late-stage biotech with no product approvals or revenue. FY-2024 net loss was $27.6 million and the auditor flagged going-concern risk. Management warns that the contemplated securities are high-risk and potentially dilutive; proceeds are needed to fund trials, operations and working capital.